Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

NCT04589832 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
6
Enrollment
OTHER
Sponsor class

Stopped This study required dose reductions to the lower dose level (Dose level -1). But this dose level (Dose level -1) was not further explored because of lack of funding.

Conditions

Interventions

Sponsor

Arkadiusz Z. Dudek, MD

Collaborators